Identification of Key Biological Pathway Routes in Cancer Cohorts

Over the last two decades, various pathway analysis methods have been proposed to investigate complex biological interactions with omics data. Topology based (TB) pathway analysis techniques are generally considered to have better performance than non-topology-based methods. However, these methods score an entire pathway as a unit, where the relevance of individual routes within the pathway is lost. In this paper, a novel route-based pathway analysis framework is discussed that can effectively process entire cohorts of gene expression data sets and identify significant pathway routes in the given cohort. The framework begins with identifying all possible transcription factor (TF) centric routes from KEGG signaling pathways. For each route in a pathway, activity scores and p-values are calculated for samples in the given cohort. Overall route activity in a cohort is assessed in terms of two summary metrics, “Proportion of Significance” (PS) and “Average Route Score” (ARS). Case studies of two human cancer cohorts from The Cancer Genome Atlas (TCGA) repository are presented.

[1]  Joel S. Bader,et al.  E-cadherin is required for metastasis in multiple models of breast cancer , 2019, Nature.

[2]  A. Bardelli,et al.  Early‐onset colorectal cancer in young individuals , 2018, Molecular oncology.

[3]  J. Alan Diehl,et al.  Cyclin D1, cancer progression, and opportunities in cancer treatment , 2016, Journal of Molecular Medicine.

[4]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[5]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[6]  K. M. Mulder,et al.  Knockdown of c‐Fos suppresses the growth of human colon carcinoma cells in athymic mice , 2012, International journal of cancer.

[7]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Paras Gupta,et al.  The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases , 2011, Journal of advanced pharmaceutical technology & research.

[9]  Yan Zhou,et al.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. , 2016, Cell reports.

[10]  C. Harris,et al.  Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.

[11]  D. Hart,et al.  Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression , 2002, British Journal of Cancer.

[12]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[13]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[14]  M. Taheri,et al.  Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer , 2018, World Journal of Surgical Oncology.